Prevail Therapeutics

Prevail Therapeutics company information, Employees & Contact Information

At Prevail Therapeutics, we are developing novel gene therapies that target the root genetic causes of Parkinson’s disease and other neurodegenerative disorders. Our mission is to translate recent advances in human genetics and gene therapy technology into medicines that slow or stop the neurodegenerative process. Our programs utilize a precision medicine approach targeting patient populations with urgent unmet needs, where there are currently no available therapies that modify the progressive course of their disorders. Prevail was formed in 2017 and we are building a team of dedicated, creative and talented individuals who share our passion for serving patients with neurodegenerative diseases. We pride ourselves on following great science, and we value collaboration, integrity and agility. We are based in the Alexandria Center for Life Science in New York City. Prevail Therapeutics was acquired by Eli Lilly and Company in January of 2021, and is now a wholly owned subsidiary of Eli Lilly. For information please visit the www.lilly.com website.
Looking for a particular Prevail Therapeutics employee's phone or email?

Prevail Therapeutics Questions

News

Gene Therapy for Frontotemporal Dementia With a GRN Mutation Gets Fast Track Status - Medical Professionals Reference

Gene Therapy for Frontotemporal Dementia With a GRN Mutation Gets Fast Track Status Medical Professionals Reference

A Conversation with Olga Uspenskaya, MD, PhD, of Prevail Therapeutics - AFTD - The Association for Frontotemporal Degeneration

A Conversation with Olga Uspenskaya, MD, PhD, of Prevail Therapeutics AFTD - The Association for Frontotemporal Degeneration

Prevail Therapeutics Announces Decisive Victory in Arbitration Brought by Alector against Prevail’s CEO - GlobeNewswire

Prevail Therapeutics Announces Decisive Victory in Arbitration Brought by Alector against Prevail’s CEO GlobeNewswire

Eli Lilly Snaps Up Gene Therapy Company Prevail Therapeutics in $1.04 Billion Deal - BioSpace

Eli Lilly Snaps Up Gene Therapy Company Prevail Therapeutics in $1.04 Billion Deal BioSpace

Exploring Causes of Frontotemporal Dementia—and Potential Treatments - Brain & Life

Exploring Causes of Frontotemporal Dementia—and Potential Treatments Brain & Life

PR001 Gets Fast Track Status for Parkinson Disease With GBA1 Mutation - Medical Professionals Reference

PR001 Gets Fast Track Status for Parkinson Disease With GBA1 Mutation Medical Professionals Reference

Passage Bio’s Gene Therapy PBFT02 Positively Impacts Biomarker Levels in Patients With Frontotemporal Dementia - CGTLive®

Passage Bio’s Gene Therapy PBFT02 Positively Impacts Biomarker Levels in Patients With Frontotemporal Dementia CGTLive®

Top Prevail Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant